BÜHLMANN Calprotectin Assay Citations

FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211. PMID:27688663.

Read more

Ulcerative Colitis Study: New Faecal Calprotectin Cut-offs

BÜHLMANN IBDoc®: Walsh, A, Kormilitzin, A. et al. New faecal calprotectin cut-off points for remission and active disease defined by UCEIS and Nancy indices in ulcerative colitis (UC).  13th Congress of ECCO 2018, Feb 14 – 17, 2018. Vienna, Austria. Highlights from this Poster “Conclusions. An FCal <180 g/g is indicative of endoscopic and histological remission. FCal
Read more

Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®

BÜHLMANN IBDoc®: Wong, A, Bourdages, R. et al. Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®.  CDDW 2018, Feb 09 – 11, 2018. Toronto, ON Canada. Highlights from this Publication “Conclusions. The IBDoc® test kit was understood by participants, with a majority of participants finding it easy to use, with an
Read more

Point of Care Testing of Fecal Calprotectin as a Substitute for Routine Laboratory Analysis

BÜHLMANN fCAL® turbo and IBDoc®: Hejla, J, Theedeb, K, et al.  Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis.  Practical Laboratory Medicine; 10 (2018) 10-14. PMID: 29234707 DOI: 10.1016/j.plabm.2017.11.002 Highlights from this Publication “This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients. Point of care
Read more